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Enhanced sphingosine-1-phosphate
receptor 2 expression underlies female
CNS autoimmunity susceptibility
Lillian Cruz-Orengo,1 Brian P. Daniels,2 Denise Dorsey,1 Sarah Alison Basak,1
José G. Grajales-Reyes,1 Erin E. McCandless,1 Laura Piccio,3
Robert E. Schmidt,4 Anne H. Cross,3 Seth D. Crosby,5 and Robyn S. Klein1,2,4
1Department

of Internal Medicine, 2Department of Anatomy and Neurobiology, 3Department of Neurology, 4Department of Pathology and Immunology, and
5Genome Technology Access Center, Washington University School of Medicine, St. Louis, Missouri, USA.

Multiple sclerosis (MS) is an inflammatory disease of the CNS that is characterized by BBB dysfunction and
has a much higher incidence in females. Compared with other strains of mice, EAE in the SJL mouse strain
models multiple features of MS, including an enhanced sensitivity of female mice to disease; however, the
molecular mechanisms that underlie the sex- and strain-dependent differences in disease susceptibility have
not been described. We identified sphingosine-1-phosphate receptor 2 (S1PR2) as a sex- and strain-specific,
disease-modifying molecule that regulates BBB permeability by destabilizing adherens junctions. S1PR2
expression was increased in disease-susceptible regions of the CNS of both female SJL EAE mice and female
patients with MS compared with their male counterparts. Pharmacological blockade or lack of S1PR2 signaling decreased EAE disease severity as the result of enhanced endothelial barrier function. Enhanced S1PR2
signaling in an in vitro BBB model altered adherens junction formation via activation of Rho/ROCK, CDC42,
and caveolin endocytosis-dependent pathways, resulting in loss of apicobasal polarity and relocation of abluminal CXCL12 to vessel lumina. Furthermore, S1PR2-dependent BBB disruption and CXCL12 relocation were
observed in vivo. These results identify a link between S1PR2 signaling and BBB polarity and implicate S1PR2
in sex-specific patterns of disease during CNS autoimmunity.
Introduction
Multiple sclerosis (MS) is an autoimmune, demyelinating disease
of the CNS that has a strong sex bias, with the female to male ratio
currently ranging from 3:1 to 4:1 (1–3). Relapsing-remitting MS
(RRMS), the most common form of the disease in women and
men, is a condition in which recurrent relapses of new neurological
dysfunction (relapses) are separated by periods of clinical stability.
The mechanisms underlying sex differences in MS and whether
they predominantly affect immune responses, CNS susceptibility
to inflammation, or both are unclear.
EAE in the inbred SJL mouse strain is commonly used to model
the sexual dimorphism observed in MS. Female SJL mice exhibit
increased sensitivity to EAE and a relapsing-remitting phenotype,
while male SJL mice exhibit monophasic disease resembling EAE
induced in both sexes of other mouse strains, such as C57BL/6.
Gonadal hormones and epigenetic regulation of sex chromosomes
are postulated to contribute to sex differences in SJL mice during
EAE and other autoimmune disorders (4, 5). Several studies also
indicate that the CNS itself may be responsible for the observed
sex differences in disease expression, primarily via alterations in
endothelial cell–mediated regulation of immune cell entry (6–9).
Studies of endothelium in peripheral organs implicate cadherins and sphingosine-1-phosphate (S1P) signaling in mediating
alterations in cadherin-dependent barrier properties between
endothelial cells (10). Cadherins are plasma membrane proteins
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associated with adherens junctions (AJs), whose expression at
cell-cell contacts depends on endocytic transport (11–13). Vascular endothelial–cadherin (VE-cadherin) expression is required for
CNS endothelial polarity and vascular lumen organization (14),
and cytokine-mediated alterations in VE-cadherin expression in
CNS endothelium influence leukocyte entry (15, 16). S1P, a bioactive metabolite of sphingolipids, is produced by erythrocytes in
the plasma, vascular and lymphatic endothelial cells, and neuronal
lineage cells within the CNS (17–19). S1P signals via 5 G protein–coupled receptors (S1PRs) to regulate various physiological
responses, including vascular permeability (20–22). Endothelia
express different combinations of S1P receptors (S1PRs), which
regulate endothelial cell survival, migration, AJ assembly, and barrier integrity (20, 21, 23). S1PRs have received considerable attention in the MS field due to recent success with the broad S1PR
inhibitor, fingolimod (FTY720-phosphate), which binds to S1PR
subtypes S1PR1, S1PR3, S1PR4, and S1PR5 but not S1PR2 (24),
and inhibits vascular endothelial cell growth factor–induced vascular permeability in vivo (22). Several in vivo studies demonstrate
roles for S1PR2 in vascular biology, including regulation of portal
vein pressure (25), the formation of atherosclerotic plaques (26),
inflammation (27), and retinal angiogenesis (28). In vitro studies
implicate S1PR2 in the regulation of vascular integrity via phosphorylation of VE-cadherin, preventing its translocation to cellcell contact sites (29). The expression or function of S1PR2 at
endothelial barriers within the CNS or during induction of CNS
autoimmunity has not been investigated.
Here, we identify a sexually dimorphic target for the treatment
of relapsing-remitting CNS autoimmunity. Microarray analysis
of specimens from naive male and female adult SJL mice revealed
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Table 1
Sexually dimorphic genes or loci in naive SJL cerebella and
frontal cortices
Fold change
(female vs. male)
Gene symbol
CB
CTX
Known X- or Y-linked loci			
Xist
Utx
Eif2s3x
Igsf1
Timp1
Ddx3y

Chromosome

3.544B
1.317B
1.348B
–1.897B
–1.519B
–9.345B

X
X
X
X
X
Y

–1.203
–1.598
–1.978

1.524B
–1.072
–1.100

X
Y
Y

–1.035
1.039
–1.037
1.021
–1.564
–1.004
–1.012
1.311
–1.367
1.016
–1.168
1.337
–1.017
1.076
1.015

1.441B
1.373B
1.400B
1.327B
–1.166
–1.411B
–1.301B
–1.092
1.006
1.415B
1.377B
–1.038
–1.339B
1.365B
1.347B

1
2
3
4
6
7
8
9
9
11
12
14
16
17
19

3.837A
1.341A
1.277
1.043
–1.215
–11.042

Novel X- or Y-linked loci
A830055109Rik
LOC673556
4930579N16Rik
Autosomal
R3hdm1
Ppp1r1c
Hsd3b2
Cort
Csda
Apoc1
Zfhx3
S1pr2
Il20rb
Foxk2
Idb2
Nefm
Sdf2l1
Adcyap1
Cd6

Summary of sexually dimorphic genes or loci in SJL cerebella (CBA)
and frontal cortices (CTXB) and chromosome locations. Four novel
autosomal loci were differentially expressed in the female cerebella
(shown in bold).

a significant increase in the expression of S1PR2 in disease-susceptible CNS regions only in females. Expression and activity of
S1PR2 were associated with decreased VE-cadherin at AJs and
reversal of endothelial cell polarity, as assessed by movement of
the abluminal chemokine CXCL12 (30–32) to lumenal locations.
Naive female SJL mice exhibited relocation of CXCL12 along venule lumina exclusively in white matter compared with naive male
SJL mice and both sexes of other murine strains. S1PR2-deficient
mice and female, but not male, SJL mice treated with the S1PR2
antagonist, JTE-013, each exhibited decreased disease severity
during EAE induced by active immunization with myelin peptide,
accompanied by diminished lymphocyte entry, persistent abluminal expression of CXCL12, and decreased BBB permeability to
fluorescein. S1PR2 appears to play an essential role in regulating
CNS endothelial polarity, which influences lumenal localizing
cues and capture of infiltrating lymphocytes.
Results
Whole transcriptome analyses of sexually dimorphic genes detects elevated
S1PR2 in disease-susceptible CNS regions in naive female SJL mice. The
inbred SJL mouse strain has been used as a model of the sexual
2572

dimorphism observed in MS, as female SJL mice are more susceptible to EAE than male SJL mice and exhibit a relapsing-remitting
disease pattern similar to that observed in patients with MS (33).
We hypothesized that sexual dimorphism in this MS model arises
from sexually dimorphic and CNS-region specific expression of
genes that regulate BBB permeability and leukocyte entry. Thus,
we used a whole transcriptome microarray to identify sexually
dimorphic RNA transcripts that are differentially expressed in disease-susceptible versus nonsusceptible CNS regions of male and
female SJL mice. Profiling total RNA from the cerebella and frontal cortices of naive female SJL mice versus male SJL mice revealed
differential expression of 44 and 23 gene transcripts, respectively,
with 20 being unique to the cerebellum (Table 1 and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI73408DS1). Sixteen of these transcripts have
uncharacterized genetic function and are only identified by their
locus link or RIKEN database numbers (Supplemental Table 1). Fifteen of these uncharacterized loci are linked to the Y chromosome,
and one is autosomal. The 3 loci that were dimorphic in both cortex and cerebellum are linked to the X or Y chromosomes, including Xist, which regulates X-chromosome inactivation (Table 1).
Of the 4 novel autosomal loci that were unique to the cerebellum,
2 were of interest for autoimmune disease: the IL-20 receptor b,
a receptor associated with skin autoimmune diseases (34–37),
and sphingosine-1-phosphate receptor 2 (S1PR2), which regulates vascular permeability in peripheral organs (refs. 29, 38, 39,
and Figure 1A). Because S1PR2 belongs to a family of G protein–
coupled receptors expressed by cells of the vascular, immune,
and nervous systems and S1PR2 signaling, in particular, disrupts
endothelial AJs, we focused our studies in CNS autoimmunity on
this protein (29). Quantitative PCR (QPCR) evaluation of sexually
dimorphic expression of S1PR2 in cerebella of SJL mice validated
microarray results (P = 0.0255) (Figure 1B). Western blot analysis confirmed microarray and QPCR data, revealing significantly
enhanced expression of S1PR2 in the cerebella of naive female SJL
mice compared with that in male SJL mice (P < 0.05), while no sexual dimorphism was observed in naive C57BL/6 mice (Figure 1C),
and whole brain extracts from S1PR2-deficient mice confirmed
antibody specificity (Supplemental Figure 1A). Of interest, Western blot examination of S1PR2 levels within the cerebella of naive
SJL-Chr YB10.S male mice compared with those of SJL male and
female mice did not suggest that a Y-chromosome polymorphism
(40) is responsible for sexually dimorphic S1PR2 expression in the
CNS of SJL mice (Supplemental Figure 2).
Because S1PR2 has known roles in vascular biology, we assessed
disruption of the BBB, via administration of sodium fluorescein to
naive male and female animals of both B6 and SJL backgrounds.
Consistent with increased S1PR2 expression in the cerebella of
naive female SJL animals, fluorescein permeability was significantly
increased in the cerebella of naive female SJL mice compared with
that in male mice (P < 0.01) (Figure 1D). Similar to wild-type B6
mice, S1PR2-deficient mice and their wild-type controls, which are
both on a 129S/B6 background, do not exhibit sexual dimorphism
and deficiency of S1PR2 does not alter BBB permeability in naive
animals (Supplemental Figure 1B). Immunohistochemical detection of extravasated albumen in CNS white matter of naive SJL
mice also exhibited sexual dimorphism (Figure 1E). Of note, sexual
dimorphism in S1PR2 expression and vascular permeability was not
observed in the spinal cord, which is a disease-susceptible CNS region
in SJL mice. In addition, alterations in levels of claudin 5, as assessed
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Figure 1
S1PR2 exhibits sexually dimorphic gene expression within the CNS of naive SJL mice. (A) Microarray analysis of S1PR2 and IL-20RB expression
within cerebella (CB) (green) of female (red circles) and male (blue circles) littermates demonstrates significant alterations compared with frontal
cortices (FCX) (purple). In box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers
indicate 10th and 90th percentiles. Data are expressed as fold change ± SEM and as individual values of Illumina probe levels. P < 0.05, ANOVA
for sex- and region-specific gene expression (cerebella only). (B) QPCR evaluation of S1PR2 expression in cortices (CTX), cerebella, and spinal
cords (SC) of same cohort. Data are expressed as mean S1PR2/GAPDH copies ± SEM for female (red bars) and male (blue bars) samples
(n = 5). *P < 0.05, 2-way ANOVA. (C) Western blot analysis of S1PR2 in cortices, cerebella, and spinal cords in male (B6: light blue bars; SJL:
blue bars) and female (B6: pink bars; SJL: red bars) C57BL/6 and SJL mice. Data are expressed as mean ± SEM densities normalized to male B6
(n = 5). *P < 0.05, 2-way ANOVA. (D) Male (light and dark blue bars) and female (pink and red bars) naive C57BL/6 and SJL mice were examined for BBB Na-Fluorescein permeability within cortices, cerebella, and spinal cords, normalized to sera values for individual mice (5–8 mice
per group). Data are reported as arbitrary fluorescence values, normalized to mean ± SEM values for naive male C57BL/6 in each CNS region.
**P < 0.01. (E) Immunohistochemical detection of albumen in cortices, cerebella, and spinal cords of naive female and male SJL mice. Scale bar:
25 μm. Images are representative of 3 images each from 2 to 3 mice per sex.

by Western blotting, did not exhibit sexual dimorphism in naive B6
or SJL mice (Supplemental Figure 3). Immunohistochemistry (IHC)
analysis of cellular sources of S1PR2 in the CNS of naive female and
male SJL mice revealed localization mostly along endothelial cells,
with some astrocytes and pericytes as additional sources (Figure 2).
Female SJL mice and humans exhibit increased vascular S1PR2 during
CNS autoimmunity. To assess sexually dimorphic alterations in BBB
permeability during CNS autoimmunity, we administered sodium
fluorescein to male and female animals of both B6 and SJL backgrounds after induction of EAE via immunization with appropriate myelin peptides. During the course of EAE, fluorescein permeability increased in all CNS regions in both sexes and strains, with
significantly higher permeability in female SJL mice compared
with that in male SJL mice at peak of disease and during remission
in cortices (peak: P < 0.05; remission: P < 0.05) and cerebella (peak:
P < 0.05; remission: P < 0.001) (Figure 3A). Expression of S1PR2
was also sexually dimorphic during EAE, as S1PR2 expression

was increased in disease-susceptible regions (cerebella: P < 0.05;
spinal cord: P < 0.001) in female SJL mice at peak of EAE, with
no detectable differences in cortices (Figure 3B). Again, no such
sexual dimorphism was observed in C57BL/6 mice. Although ovariectomy and estrogen exposure affect disease in female SJL mice
(33, 41–45), levels of S1PR2 expression in all CNS regions of naive
female SJL mice or of female SJL mice immunized with proteolipid
protein epitope 139–151 (PLP139–151) were unaffected by ovariectomy, with or without 17β-estradiol replacement (Supplemental
Figure 4). Of note, sham-ovariectomized and ovariectomized mice
were evaluated when they attained clinical scores of 2, whereas
ovariectomized mice treated with 17β-estradiol did not develop
symptomatic EAE. Thus, suppression of clinical symptoms by
17β-estradiol in PLP139–151–immunized mice did not affect CNS
levels of S1PR2 expression. These data are also consistent with
studies demonstrating that 17β-estradiol does not affect systemic
inflammation in the setting of active immunization (41).

The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 6   June 2014

2573

Downloaded on July 6, 2014. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/73408

research article

Figure 2
S1PR2 is primarily expressed by CNS endothelial cells. (A) Immunofluorescence detection of S1PR2 (red) in female and male SJL endothelial
cells (CD31, green), located in the cortex, cerebellum, and spinal cord and in spinal cord astrocytes (GFAP, green). Arrowheads identify S1PR2+
astrocytes. (B) Immunofluorescence detection of S1PR2 (green) in female and male SJL pericytes (PDGF-Rβ, red), located in the cortex, cerebellum, and spinal cord. (C) Immunofluorescence detection of S1PR2 (red) in spinal cords of 129S/B6 wild-type and S1pr2–/– mice. All nuclei were
stained with Topro3 (blue). Scale bar: 25 μm. Data are representative of 10 images each from 5 female and 5 male animals.

S1PR2 immunoreactivity was localized to endothelium, vessel-associated astrocytes, and occasional pericytes within the
CNS of SJL mice with EAE (Figure 3C) and within human postmortem cerebellar specimens derived from patients with and
without MS (Supplemental Table 2 and Figure 4, A and B). Furthermore, quantitative IHC assessment of human specimens
showed significantly higher levels of vessel-associated S1PR2 in
patients with MS compared with that in patients without MS
(P = 0.01) and a trend toward increased S1PR2 expression in
female patients with MS compared with that in male patients
with MS (Figure 4C). Of interest, the highest levels of S1PR2
expression in female patients with MS were in those with RRMS
(2 cases), and the 1 male patient with high levels of S1PR2 had
a history of occipital head trauma. These results suggest that
S1PR2 may play a role in sexually dimorphic patterns of BBB
dysfunction in the setting of CNS autoimmunity.
Clinical disease severity and BBB permeability during EAE are reduced
by pharmacologic or genetic inactivation of S1PR2. To investigate
whether S1PR2 modulates the pathogenesis of EAE, we evaluated
clinical disease scores in the setting of both pharmacologic blockade and genetic deletion of S1PR2. Female SJL mice treated with
2574

the specific S1PR2 antagonist JTE-013 (1.5 mg/kg) (46), beginning when mice reached a clinical score of 2 and continuing for
10 (Figure 5A, top) or 30 (Figure 5A, bottom) days, exhibited less
severe daily clinical scores (P < 0.0001, both lengths of treatment),
maximum severity scores (P < 0.0001, both lengths of treatment),
and mean cumulative scores (P < 0.01 for 10 days treatment,
P < 0.001 for 30 days treatment), while male SJL mice did not
respond to treatment (Supplemental Figure 5). No changes in
body weight were observed after JTE-013 treatment, regardless of
treatment duration (Supplemental Figure 6, A–C). Consistent with
clinical assessments, H&E staining revealed significantly fewer
inflammatory foci within the white matter of both spinal cords
(P < 0.01) and cerebella (P < 0.05) of JTE-013 mice compared with
that in vehicle-treated female SJL mice at peak of EAE (Figure 5B),
and cerebellar lesions were significantly reduced (P < 0.05) during
remission. Luxol fast blue (LFB) staining further revealed that JTE013 treatment reduced demyelination of spinal cords and cerebellar
white matter during peak and remission phases of EAE (Figure 5B).
Female SJL mice with EAE treated with JTE-013 for 5 days also
exhibited significantly reduced fluorescein permeability in both
cerebella (P < 0.001) and spinal cords (P < 0.01), compared with
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Figure 3
Female SJL mice exhibit sexually dimorphic enhancement of BBB permeability and S1PR2 expression during EAE. (A) Male and female C57BL/6
and SJL mice at peak of EAE (clinical score of 3 to 4) or first remission (clinical score of 2) were examined for BBB permeability to Na-Fluorescein
within cortices, cerebella, and spinal cords, normalized to sera values for individual mice (5–8 mice per group). Data are reported as arbitrary
fluorescence values, normalized to mean values for naive male C57BL/6 in each CNS region. (B) Protein lysates from CNS regions of male and
female C57BL/6 and SJL mice at peak of EAE (clinical scores of 3 to 4) were probed for S1PR2 (red), with β-tubulin (green) as a loading control.
Data are reported as density values of S1PR2 normalized to density values for β-tubulin. Data are normalized to mean values for male C57BL/6
mice in each CNS region. (A and B) Bar graphs depict mean ± SEM findings for male (B6: light blue bars; SJL: blue bars) and female (B6: light
red bars; SJL: red bars) for 4 mice per group. *P < 0.05; ***P < 0.001, 2-way ANOVA. (C) Immunofluorescence detection of S1PR2 (red, top and
middle; green, bottom) in vessels (CD31, green), astrocytes (GFAP, green), and pericytes (PDGF-Rβ, red, bottom) in cortices, cerebella, and
spinal cords of female SJL mice at peak of EAE. All nuclei were stained with Topro3 (blue). Scale bar: 25 μm. Data are representative of 10 images
each from 5 male and 5 female animals. Arrows indicate areas of colocalization.

vehicle controls (Figure 5C, top) and a significant reduction in
spinal cord permeability after prolonged treatment for 30 days
(P < 0.01) (Figure 5C, bottom). Similar results were observed via
immunohistochemical detection of extravasated albumen within
the white matter of diseases mice (Supplemental Figure 7A).

Consistent with results after antagonist treatment, S1PR2-deficient mice immunized with MOG35–55 exhibited significantly
decreased severity of EAE compared with that of wild-type controls, indicated by lower daily clinical scores (P < 0.0001), maximum severity scores (P < 0.0001), and mean cumulative scores
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Figure 4
BBB expression of S1PR2 is increased in MS. (A) Endothelial cell (CD31, green) and (B) astrocyte (GFAP, green) localization of S1PR2 (red) in
female and male cerebellar tissue obtained from patients with and without MS. Nuclei are counterstained with Topro3 (blue). (A) Control stains, in
which sections were first blocked with immunogen (1 mg/ml) prior to detection of CD31 (green) and S1PR2 (red), are included. Scale bar: 25 μm.
(C) Quantification of amounts of vessel-associated S1PR2 fluorescence in female (red circles) and male (blue circles) samples from patients
with and without MS. Levels of S1PR2 fluorescence were determined by examining S1PR2 staining in venule ROIs in 10 images per patient (4–6
patients per group), normalized by area of CD31 staining to control for size and numbers of vessels. Note that the outlier in the male MS group
also had a history of occipital head trauma. *P < 0.05. Horizontal bars represent geometric means.

(P < 0.0001) (Figure 6A). S1pr2–/– animals also exhibited less demyelination and fewer inflammatory foci during peak of EAE, compared with wild-type mice, in the spinal cords (P = 0.03) but not
the cerebella (Figure 6B), in addition to significant reductions in
fluorescein permeability in the spinal cords during both acute
(P < 0.01) and chronic (P < 0.01) EAE (Figure 6C). There was also less
detection of extravasated albumen in the spinal cords of S1pr2–/–
mice compared with that in wild-type animals at peak of disease
(Supplemental Figure 7B).
S1PR2 signaling enhances BBB permeability via caveolin-endocytosis,
Rho/ROCK, and CDC42-dependent pathways. To further assess the
impact of S1PR2 signaling on BBB function, we used a well-characterized transwell in vitro model of the BBB consisting of human
cerebral microvascular endothelial cells (HCMECs) grown on
2576

porous filter membranes over primary human astrocytes (47).
Barrier integrity was evaluated by electrode recording of transendothelial electrical resistance (TEER). Treatment with exogenous
S1P permeabilized in vitro BBBs in a dose-dependent manner over
the course of 4 hours, indicated by significant reductions in TEER
(P < 0.001, all comparisons) (Figure 7A). This disruption of barrier integrity was S1PR2 dependent, as treatment with an S1PR2
antagonist (Figure 7B), but not an S1PR1 antagonist (Figure 7C),
rescued TEER reduction after S1P treatment. Moreover, treatment
with an S1PR1-specific agonist led to a small increase in TEER in
both vehicle- and S1P-treated cultures (P < 0.05) (Supplemental
Figure 8A), in contrast to the TEER decreases produced by S1P via
S1PR2. Use of RNA interference to specifically knockdown S1PR1
and S1PR2 similarly demonstrated S1PR2-dependent disruption
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Figure 5
S1PR2 inactivation ameliorates EAE and alterations in BBB permeability. (A and B) Female SJL mice immunized with PLP139–151 were treated
with vehicle or JTE-013 (JTE; 1.5 mg/kg) when mice reached a clinical score of 2. (A) Clinical scores of mice treated for 10 (top) or 30 (bottom)
consecutive days ± SEM. Insets show means of cumulative scores (MCS) and of highest severity scores (MHSS) ± SEM for 10 to 15 mice per
group. (B) H&E-stained (left panels) and LFB-stained (right panels) sections from spinal cords and cerebella of vehicle- and JTE-treated mice at
peak of EAE (top) or remission (bottom). Bar graphs depict mean numbers of white matter lesions (WML) within both CNS regions for either peak
or remission ± SEM for 5 to 6 mice per treatment group. Arrows highlight inflammatory foci. Scale bar: 25 μm. (C) Relative BBB permeability of
cortex, cerebellum, and spinal cord tissues from vehicle- and JTE-treated mice at peak of EAE or remission. Data are depicted as mean fluorescence intensity, normalized against sera values for individual mice ± SEM for 6 mice per treatment group, with means normalized against mean
values for untreated, naive controls. *P < 0.05; **P < 0.01; ***P < 0.001.

of barrier integrity (Supplemental Figure 9, A and B). Further
characterization of the signaling components that contribute to
S1PR2 dysregulation of the in vitro BBB revealed that pharmacological blockade of the caveolin-dependent endocytic pathway
(Figure 7D) prior to S1P treatment prevented TEER reductions
(P < 0.001), while blockade of clathrin-dependent endocytosis
(Supplemental Figure 8B) or macropinocytosis (Supplemental
Figure 8C) produced either small or no changes in TEER after S1P
administration, respectively. TEER reductions after S1P treatment
were also prevented by pretreatment with inhibitors of the Rho
GTPase effectors Rho/ROCK (P < 0.001) (Figure 7E) and CDC42
(P < 0.001) (Figure 7F) but not Rac (Supplemental Figure 8D).
S1PR2 signaling leads to breakdown of AJs and loss of polarized expression of CXCL12 on basolateral/abluminal surfaces. We next examined
whether S1PR2-dependent disruption of BBB function resulted
in molecular changes to the structure of the BBB endothelium.
Similar to results with TEER recording, S1P treatment resulted
in a breakdown of AJs, indicated by loss of intensity and discreteness of VE-cadherin staining at intercellular borders (Figure 7G,
left). Diminished AJ integrity was also associated with a loss of
polarized protein expression on the apical and basolateral surfaces of endothelial cells, as assessed via z-plane confocal microscopy (imaging on same plan of microscopy z axis) for canonical
markers of apical (γ-glutamyltransferase-1 [GGT]) and basolateral
(CXCL12) BBB surface markers (Figure 6G, right). Again, loss of AJ
integrity and polarized GGT/CXCL12 expression after S1P treatment was specific to S1PR2, as it could be reversed by JTE-013
treatment (Figure 7H) but not by treatment with a specific antagonist (Figure 7I) or agonist of S1PR1 (Supplemental Figure 8E).
Knockdown of S1PR2, but not S1PR1, RNA in the context of S1P

treatment also led to loss of AJ integrity (Supplemental Figure 9C).
Similarly, pretreatment with inhibitors of caveolin-dependent
endocytosis (Figure 7J) and Rho/ROCK or CDC42 (Figure 7,
K and L) prevented loss of AJs and endothelial polarity, while inhibition of clathrin-dependent endocytosis, macropinocytosis, and
Rac (Supplemental Figure 8, F–H) had no effect.
Given the mouse strain- and sex-specific differences in CNS levels of expression of S1PR2, we next analyzed polarized CXCL12
expression at the BBB in naive female and male mice of various
strains susceptible to EAE via quantification of fluorescence intensity across vessels using confocal microscopy (32). In the spinal
cord white matter, CXCL12 expression was primarily abluminal on
the vessels of male SJL mice and in C57BL/6 and B10.PL mice of
either sex, whereas vessels in female SJL mice instead exhibited a
unique pattern of primarily lumenal CXCL12 expression (Supplemental Figure 10A). Similar analyses of brain vasculature in female
and male SJL mice revealed a predominantly lumenal display of
CXCL12 in the brainstem and cerebellar white matter tracts in the
female mice only, while vessels in all brain regions of male mice
and in supratentorial brain regions of female mice exhibited proper
abluminal patterns of CXCL12 (refs. 31, 32, and Supplemental Figure 10B). After induction of EAE, inflamed vessels within infratentorial regions of male mice exhibited a shift in CXCL12 expression
from abluminal to lumenal locations, while female mice exhibited
loss of CXCL12 expression (Supplemental Figure 11), as previously
reported (30). To test whether inactivation of S1PR2 altered BBB
expression of CXCL12 in vivo, we analyzed the location of CXCL12
at CNS vasculature within the cortices, cerebella, and spinal cords
of female SJL mice treated with vehicle or JTE-013 as well as wildtype mice and S1pr2–/– mice at peak of disease. JTE-013–treated
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Figure 6
S1PR2 deficiency ameliorates EAE and alterations in BBB permeability. Wild-type and S1pr2–/– mice were immunized with MOG and followed
for disease progression. (A) Clinical EAE scores ± SEM. The inset shows mean of cumulative score and highest severity score ± SEM for 10 to
15 mice per genotype. (B) H&E-stained (left panels) and LFB-stained (right panels) sections derived from spinal cords and cerebella of WT and
S1pr2–/– mice at peak of EAE. Scale bar: 25 μm. Bar graphs depict mean numbers of white matter lesions within both CNS regions ± SEM for
4 to 6 mice per genotype. (C) Relative BBB permeability of cortex, cerebellum, and spinal cord tissues derived from WT and S1pr2–/– mice at
peak and chronic stages of monophasic EAE. Data are depicted as mean fluorescence intensity, normalized against plasma values for individual
mice ± SEM for 4 to 6 mice per genotype, with means normalized against mean values for WT naive controls. *P < 0.05; **P < 0.01; ***P < 0.001.

female SJL mice exhibited significantly increased levels of abluminal CXCL12 in infratentorial CNS regions (cerebella: P < 0.01;
spinal cords: P < 0.05), with no changes observed in cortical vessels
(Figure 8, A and B). Similarly, S1pr2–/– mice exhibited significantly
higher levels of abluminal CXCL12 within spinal cord white matter
regions than wild-type controls at peak of EAE (P < 0.001) (Figure 8,
C and D). These data suggest that S1PR2 activity dysregulates
proper abluminal expression of CXCL12 and that this affects disease course during CNS autoimmunity.
Discussion
We have defined a sexually dimorphic role for S1PR2 in the disruption of polarity at the BBB. Elevated levels of S1PR2 were detected
in EAE-susceptible CNS regions in female SJL mice compared
with that in male SJL mice and compared with C57BL/6 mice of
both sexes. Consistent with this, antagonism of S1PR2 ameliorated clinical disease severity during EAE in female, but not male,
SJL mice immunized with PLP139–151 to induce EAE. S1PR2 was
detected on endothelial cells and vasculature-associated astrocytes within the CNS and was significantly higher in white matter
regions of patients with MS compared with controls without MS,
with female patients with MS exhibiting higher levels than male
patients. In vivo and in vitro studies evaluating the role of S1PR2
in BBB permeability revealed its critical involvement in loss of apicobasal expression of canonical markers of BBB polarity, including
the chemokine CXCL12 (30–32). As abluminal levels of CXCL12
control parenchymal entry of leukocytes (32, 48), our data provide strong evidence that S1PR2 acts as a general regulator of BBB
fence function and may be targeted to treat MS in certain patients.
Recent research has characterized genetic, hormonal, and environmental contributions to sex bias in MS; however, an understanding of sexual dimorphism in CNS autoimmunity has yet to
result in novel, successful therapeutics that target these mechanisms (4, 5, 49, 50). This report identifies a potential contributor to MS sex bias and is the first to identify a sexually dimorphic
regulator of the BBB. The identification of sexually dimorphic
changes in mRNA levels within different CNS regions was not
2578

due to direct effects of sex steroids on transcriptional programs.
Thus, analysis of S1PR2 expression in the cerebella of SJL/J-Chr
YB10.S male mice did not link sexually dimorphic effects to the
Y chromosome (40), and analysis of S1PR2 expression in the CNS
of naive or diseased, ovariectomized mice, with or without estradiol replacement, also did not reveal acute regulation of S1PR2 by
gonadal hormones. Most current therapies for RRMS are immunomodulators, while others address the consequences of relapses
by managing symptoms or improving function (51, 52). However,
these drugs often have off-target side effects, because they do not
specifically target myelin-reactive leukocytes (53, 54). Targeting
S1PR2 may avoid common off-target effects and maybe more CNS
specific than the use of FTY720, which targets several S1PRs but
not S1PR2 (24). As S1PR2 also maintains germinal center B cells
(55), its blockade is unlikely to lead to the lymphopenia observed
with FTY720. FTY720 is also associated with severe adverse events,
including fatal herpesvirus infections, hemorrhagic focal encephalitis, and vasospasm of the brachial artery, mostly mediated by
S1PR3 signaling after prolonged use (56–62).
S1PR2 activity in our study was associated with several critical markers of endothelial barrier dysfunction, including higher
transendothelial permeability and loss of apicobasal polarity, in
vitro and in vivo. Our findings corroborate in vitro prior reports,
suggesting counterbalancing roles of S1PR1 and S1PR2 in maintaining vascular endothelial integrity via Rho GTPase signaling,
with S1PR1 enhancing barrier function primarily via Rac activation (20, 63, 64) and S1PR2 disrupting barrier function through
cytoskeletal contraction, stress fiber formation, and junction protein disassembly via RhoA/ROCK signaling (29, 65). Our results also
implicate potentially complementary roles for RhoA and CDC42, a
key regulator of cellular polarity (66), in S1PR2-mediated BBB dysregulation, perhaps by convergent downstream effector signaling
(67). The caveolin-dependent endocytic pathway, but not the clathrin-dependent endocytic or macropinocytic pathways, also appears
to be an important mediator of barrier dysregulation via S1PR2,
likely due to the enrichment of S1PRs in close proximity with their
associated effectors in membrane caveolae (64), though evidence
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Figure 7
S1PR2 signaling dysregulates CNS
endothelial barrier structure and function through Rho/ROCK, CDC42,
and caveolin endocytosis-dependent
pathways. (A–F) Paracellular permeability of in vitro BBB cultures was
assessed by electrode recording of
TEER, reported in Ω/cm2. (A) TEER
after treatment of in vitro BBB cultures
with 10, 100, or 1,000 nM exogenous
S1P for 4 hours or (B and C) 1,000 nM
S1P for 4 hours with or without (B)
1,000 nM JTE-013 at 2 hours or (C)
the S1PR1-specific antagonist W146
(1,000 nM) at 2 hours. (D–F) TEER
after 1,000 nM S1P treatment of BBB
cultures pretreated for 2 hours with
(D) the caveolin endocytosis inhibitor MBCD (10 mM), (E) Rho-associated protein kinase (ROCK) inhibitor
H1152P (10 nM), or (F) CDC42 inhibitor ML141 (100 nM). TEER values
are mean ± SEM of 6 to 9 replicates
of 2 to 3 independent experiments.
***P < 0.001, repeated-measures 2-way
ANOVA. (G–L) Immunocytochemical
staining of AJs in HCMEC/D3 cells
via labeling of VE-cadherin (red, left
and middle panels; scale bar: 30 μm)
and confocal z-stack reconstruction of
HCMEC/D3 cells (right panels; scale
bar: 15 μm), demonstrating polarized expression of canonical apical
marker GGT-1 (green) and basolateral
CXCL12 (red) after treatment with (G)
vehicle or 1,000 nM S1P for 4 hours
followed by treatment with (H) JTE, (I)
W146, (J) MBCD, (K) H1152P, or (L)
ML141 treatment at 2 hours. Inhibitor
concentrations in H–L are identical to
those in B–F. Immunocytochemical
images are representative images of 2
to 3 independent experiments. IC, isotype controls.
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Figure 8
In vivo S1PR2 inactivation preserves BBB polarity during EAE. Detection of CD31 (green) and CXCL12 (red) within cortices, cerebella, and
spinal cords of (A and B) female SJL mice treated with vehicle or JTE-013
(1.5 mg/kg) or (C and D) wild-type and S1pr2–/– mice, all at peak of
EAE. (A and C) Nuclei have been stained with Topro3 (blue). Scale bar:
10 μm. Data are representative of approximately 30 images each from
3 to 5 mice per treatment group. Quantification of fluorescence intensity
during confocal microscopy for CXCL12 (red lines) and CD31 (green
lines) is shown below microphotographs. Arrows indicate location transected in line plot depictions. (B and D) Quantitative analysis of location of CXCL12 expression on CD31+ venules within CNS tissues of (B)
vehicle- and JTE-013–treated and (D) wild-type and S1pr2–/– mice at
peak of EAE. Data are derived from venules analyzed within 30 images
per brain region for 3 to 5 mice per treatment group and are expressed
as (mean ± SEM) percentages of vessels with abluminal, lumenal, or
absent CXCL12 signal. *P < 0.05; **P < 0.01; ***P < 0.001 for χ2 comparisons between CXCL12 locations within each brain region.

also suggests that AJs can be disrupted via caveolin-mediated endocytosis of junction proteins (13, 68, 69). Of interest, interferon-beta,
which prevents inflammatory events in RRMS, promotes stability
of VE-cadherin (70), suggesting that the specific targeting of this
pathway could greatly improve therapy. Finally, as S1PR2 antagonism does not affect receptor expression by endothelial cells (71),
targeting the receptor to prevent alterations in BBB permeability
should not lead to long-term effects on BBB function.
Association of S1PR2 with endothelial permeability by VE-cadherin–mediated tight junction dysfunction was first reported by
Sanchez et al. using an in vitro model of HUVECs genetically modified to express S1PR2 (72). However, the observed amelioration
of EAE in S1PR2-deficient mice could be attributed potentially
to other immune mechanisms that do not incorporate effects
of endothelial barriers. Among the possibilities are the effects of
receptor deficiency on astrocytes or pericytes (73–76); the absence
of antigen capture, as observed in vitro for Langerhans cells (77)
and alveolar macrophages (78); or loss of B cell retention at germinal centers (79, 80), which could alter their ability to function as
effector or antigen-presenting cells within the CNS. Last, S1PR2
signaling is required for degranulation and cytokine release by
activated mast cells (81, 82), which have been implicated in the
neuropathogenesis of MS and EAE (83).
We reported previously that postcapillary venules in the center of MS lesions display the normally abluminal chemokine,
CXCL12, aberrantly along lumenal surfaces (30–32, 84). In our
study, altered patterns of CXCL12 expression at the BBB were
found to be associated specifically with MS compared with other
neuroinflammatory conditions, including viral encephalitis and
CNS lymphoma (31). Redistributed CXCL12 was associated with
increased activation of CXCR4 on leukocytes within vessel lumen,
suggesting that altered CNS vasculature polarity increases leukocyte capture at endothelial cell surfaces. The finding that humans
with susceptibility for MS exhibit high levels or sexually dimorphic expression of S1PR2 suggests that the molecule may underlie susceptibility to CNS autoimmunity and might be a diseasemodifying target in MS, similar to that observed in the female
SJL mouse. The identification of S1PR2 as a target for BBB stabilization that preserves CXCL12 polarity and therefore immune
privilege is an exciting advance toward the development of novel
MS therapies that limit CNS inflammation without compromising immune function.

Methods
Animals. SJL/JOrlCrl mice (SJL, Charles River); C57BL/6, C57BL/10, and
SJL/J-Chr YB10.S mice (The Jackson Laboratory); B6129SF1 and 129S6/
SvEvTac mice (Taconic Farms); and S1pr2–/– mice were maintained in
pathogen-free conditions (Department of Comparative Medicine, Washington University, St. Louis, Missouri, USA). The S1pr2–/– mice, which are
on a B6129S background, were generated and genotyped as previously
described (85). All mice were 10 weeks old when used for experiments.
Microarray analysis. Naive female and male SJL littermates (n = 6) were
intracardially perfused with RNAlater (Ambion, Life Technologies), followed by dissection of the cerebella and frontal cortices (2 mm). Tissue
was quickly frozen in TRIzol (Ambion, Life Technologies), and RNA was
extracted via standardized protocols. Transcriptional profiling was done
using the Illumina Mouse6 Expression BeadChip v2 (Illumina Inc.). 100 ng
total RNA was used to produce an amplified pool of biotin-labeled RNA
corresponding to the polyadenylated mRNA fraction. Biotinylated RNA
was hybridized to the array and stained with fluorescently labeled antibiotin antibody. Then, the BeadChip was scanned on an Illumina
BeadArray Reader (Illumina Inc.). Raw data were imported into Partek
Genomics Suite (Partek Incorporated) for further characterization of sexually dimorphic gene expression in female cerebella. Microarray data were
deposited in GEO (accession no. GSE55718).
Antibodies. The following antibodies were used for IHC or Western blotting: goat anti-mouse albumin conjugated to HRP (Novus); biotinylated
rabbit polyclonal anti-human CXCL12 (Peprotech); rabbit anti-S1PR2/
Edg-5 and rabbit anti-S1P1/Edg-1 antibodies (Acris Antibodies Inc.);
mouse anti–β-tubulin (Sigma-Aldrich); monoclonal mouse anti-human
VE cadherin, monoclonal rat anti-mouse, and rat anti-human CD31
(BD Bioscience); mouse monoclonal anti-human glial fibrillary acidic
protein (GFAP) and goat anti-mouse PDFG-Rb (R&D Systems); rabbit
anti-VE cadherin/phospho Y658 and rabbit anti–GGT-1 (Abcam Inc.); rat
anti-human GFAP (Invitrogen, Life Technologies); IgG isotype antibodies (mouse and rabbit, Invitrogen, Life Technologies; rat, BD Bioscience);
conjugated-secondary antibodies, streptavidin conjugates, and nuclear
stains (Molecular Probes); and IRDye-conjugated secondary antibodies
for Western blots (LI-COR Biosciences Inc.).
QPCR. Total RNA derived from CNS tissues was prepared and QPCR was
performed as previously described (86). Amplification of S1PR2 was done
using 5′-ATGGGCGGCTTATACTCAGAG-3′ (sense) and 5′-GACGGAGAAGATGGTGACCAC-3′ (anti-sense) primers as reported by Edsbagge
(87). QPCR products were validated via sequencing by the Protein and
Nucleic Acid Chemistry Laboratory at Washington University.
Western blotting for S1PR2 in murine CNS. Protein lysates (40 μg) of CNS tissues derived from 10-week-old SJL and C57BL/6 mice of both sexes (n = 8)
and after ovariectomy, with and without treatment with 17β-estradiol or
placebo, were prepared in RIPA buffer supplemented with 1:100 protease
inhibitor cocktail and 1:100 phosphatase inhibitor cocktail-3 (all from
Sigma-Aldrich) and resolved with 10% Bis-Tris gels and transferred onto
iBlot Nitrocellulose transfer membranes (both from Invitrogen) according to standard protocols. Blots were probed with polyclonal rabbit antiS1PR2 antibody. Total protein loading per lane was evaluated with mouse
anti–β-tubulin antibody. This was followed by incubation with IRDye-conjugated secondary antibodies (LI-COR). Blots were imaged with the Odyssey fluorescent scanning system (LI-COR).
Ovariectomy and hormone replacement in female SJL mice. Female SJL mice
were ovariectomized at 6 weeks of age mice prior to sexual maturity via standard protocols (33). Briefly, anesthetized animals underwent a 1-cm transverse midlumbar skin incision, followed by blunt dissection of underlying
musculature. The ovarian fat pad was exteriorized, ovarian vessels were
ligated, and ovaries were excised, followed by skin closure with nonabsorb-
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able sutures. Hormonal replacement was initiated 14 days after ovariectomy
by subcutaneous implantation of either 0.25 mg 17β-estradiol or placebo
(vehicle) 21-day release pellets (Innovative Research of America). A cohort
of these mice was immunized with PLP139–151, together with sham-ovariectomized mice, to induce EAE 7 days after hormone replacement. Immunized
animals were followed for EAE progression by monitoring clinical score and
body weight. Tissues were obtained from sham-ovariectomized and placebo-treated mice when they reached a score of 2 at 14 days after immunization and from 17β-estradiol–treated mice, which remained free of disease,
at 21 days after immunization. Protein lysates were prepared from CNS tissues, while uteri and the upper third of vaginas of all mice were drop-fixed
in 4% PFA for 48 hours. Following fixation, uterine tissue was trimmed of
fat and connective tissue prior to determination of uterine weight.
EAE induction and in vivo treatment with JTE-013. EAE was induced in SJL/J
mice via active immunization with proteolipid protein (PLP139–151; 200 μg)
(GenScript USA Inc.) emulsified in complete Freund’s adjuvant containing
Mycobacterium tuberculosis (H37Ra; Difco Laboratories). In addition, mice
were injected with 200 ng pertussis toxin (List Biologicals Laboratories Inc.)
at the time of immunization and 2 days after. Mice were graded for clinical
manifestations of EAE by the following criteria: 1, tail weakness; 2, difficulty
righting; 3, hind limb paralysis; 4, forelimb weakness or paralysis; 5, moribund or dead. JTE-013 (1.5 mg/kg; Cayman Chemical Company) or vehicle
(25% ETOH) was administered to mice daily via intraperitoneal injection, as
previously described (46), when they achieved a clinical score of 2. B6129SF1
and S1pr2–/– mice were immunized similarly with 200 μg myelin oligodendrocyte glycoprotein (MOG35–55; GenScript USA Inc.) and 200 μg M. tuberculosis
adjuvant. C57BL/6 mice were immunized as previously described (32).
In vivo assessment of BBB permeability. Mice were intraperitoneally injected
with fluorescein sodium salt (100 mg/ml, Sigma-Aldrich), followed by
collection of blood, intracardial perfusion, and harvesting of CNS tissues.
Homogenates and sera were incubated overnight at 4°C at 1:1 dilution in
2% trichloroacetic acid (Sigma-Aldrich) and diluted in equal volumes of
borate buffer, pH 11 (Sigma-Aldrich). Fluorescence emission at 538 nm
was determined via a microplate reader, Synergy H1, and Gen5 software
(both from BioTek Instruments Inc.). Tissue values were standardized
against plasma values for individual mice.
Human subjects. The use of human postmortem biopsies for this study was
approved by the Human Studies Committee of Washington University. Postmortem CNS tissue from 2 groups of patients was studied: 11 patients with
clinically defined MS followed in the Washington University Multiple Sclerosis Center and 9 control individuals without histories of MS (Supplemental
Table 2). The control group consisted of 8 patients without any clinical histories of neurological disease and 1 patient with a history of CNS lymphoma.
IHC of S1PR2 in human CNS. Human postmortem specimens were collected within 18 hours after death from 5 female and 5 male patients
with MS and the same number of non-MS controls. Tissue preparation
and evaluation of extent of inflammation were performed as previously
described (31). For IHC, tissue sections were hydrated and fixed in 4%
paraformaldehyde, blocked in 0.1% Triton X-100 and 10% goat serum, followed by incubation with rabbit anti-S1PR2, rat anti-human CD31, mouse
anti-human GFAP, and/or monoclonal mouse anti-human VE cadherin
antibodies. Primary antibodies were detected with goat anti-rabbit Alexa
Fluor 555, anti-rat Alexa Fluor 488, or goat anti-mouse Alexa Fluor 488
antibodies, as appropriate, followed by To-Pro-3 nuclear staining, confocal microscopy (Carl Zeiss USA), and quantitative analysis with Volocity
3D Image Analysis software (PerkinElmer Inc.). HRP-conjugated primary
antibodies were detected via development in DAB solution (Cell Marque).
Histological and immunohistochemical analyses of murine samples. Murine
CNS tissues underwent histological analyses (H&E; LFB staining) and IHC
detection of CD31, GFAP, PDFG-Rβ, VE-cadherin, and CXCL12, as per2582

formed previously (30). Analysis of polarized expression of CXCL12 across
vasculature was performed as previously described (32). IHC detection of
S1PR2 was performed in a fashion similar to that outlined for human CNS
tissues. Visualization was done by confocal microscopy, as described above.
Preparation of in vitro human BBB. In vitro human BBB cultures were generated using HCMEC/D3, an endothelial cell line developed from brain
tissue derived from the temporal lobe of an adult human female with epilepsy (88). HCMEC/D3 cells were cocultured with primary human astrocytes (ScienCell), within a transwell system in which TEER values (Ω/cm2)
were measured via chopstick electrode recording with an EVOM apparatus
(World Precision Instruments), as previously described (47). Resistance values are reported as recorded values for each replicate minus the resistance
of cell-free inserts (∼90 Ω) measured alone. Measurements were taken
24 hours after initial seeding of endothelial cells (day 1); subsequent measurements were taken daily for 10 days, at which point cultures were ready
for experimentation. Changes in permeability were evaluated via TEER
measurements after vehicle or S1P (Cayman Chemical Company) was added
to top and bottom chambers (10–1,000 nM) and incubated for 2 hours,
followed by addition of vehicle or JTE-013 (10–1,000 nM). Similar experiments were done using the following agents: S1PR1-specific agonist, W146
(1,000 nM), and S1PR1-specific antagonist, SEW2871 (1,000 nM, both
from Cayman Chemical Company), as well as caveolin endocytosis inhibitor, methyl-β cyclodextrin (MBCD, 10 nM); clathrin endocytosis inhibitor, chlorpromazine (10 μg/ml); or the macropinocytosis/PI3K inhibitor,
wortmannin (100 nM, all from Sigma-Aldrich). To determine the effector
molecules involved in S1PR2 signaling, we also pretreated for 2 hours with
the Rac1 inhibitor, Z62954982 (1,000 nM, Cayman Chemical Company),
the Rho/ROCK inhibitor, H-1152P (10 nM, Cayman Chemical Company),
and the CDC42 inhibitor, ML141 (100 nM, Tocris, R&D Systems).
In vitro RNA interference. HCMEC/D3 cells in BBB cultures or grown
on chamber slides were treated with 25 nM siRNA SMARTpools against
S1PR1, S1PR2, or a nontargeting control pool (ON-TARGETplus, ThermoScientific) complexed with a 1:500 dilution of DharmaFect 1 transfection
reagent (ThermoScientific) in antibiotic-free culture medium for 48 hours.
Knockdown was confirmed via immunocytochemical analysis of S1PR1
and S1PR2 protein expression. Following siRNA treatment, cells were
rinsed 3 times with PBS, returned to normal culture medium, and immediately used for immunostaining or TEER measurement experiments.
Immunocytochemical evaluation of in vitro human BBB. Analysis of polarized
expression of CXCL12 within HCMEC/D3 cells was performed after fixation with 4% paraformaldehyde for 60 minutes and permeabilization with
0.1% Triton X-100 and 10% goat serum for 30 minutes at room temperature. HCMEC/D3 cultures were incubated with primary antibodies against
GGT-1, VE-cadherin, and biotinylated CXCL12 in 10% goat serum for
60 minutes at room temperature. Cells were washed 3 times in 1X dPBS
and then incubated in goat anti-rabbit Alexa Fluor 555 and goat antimouse Alexa Fluor 488 or Alexa Fluor 555 and streptavidin–Alexa Fluor
555 secondary antibodies in 10% goat serum for 15 minutes at room
temperature. Cells were washed, counterstained with To-Pro-3, and coverslipped before being visualized via confocal microscopy.
Statistics. All microarray statistical analyses for the characterization of
sexually dimorphic gene expression in female cerebella were performed
using Partek Genomics Suite (Partek Incorporated). Data were filtered
for detectable probes (Illumina detection using P < 0.05 in at least one
sample yielded 27,333 probes), quantile normalized by CNS region, and
submitted to 2-way ANOVA for sex- and region-specific gene regulation.
Transcripts that demonstrated upregulation or downregulation of >1.3
with a false discovery rate <0.2 were selected for further characterization.
Two-tailed, Student’s t test was used to determine the statistical significance of immunohistochemical, mean maximal disease severity, and
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cumulative clinical score analyses. Statistical significance of qRT-PCR,
disease severity curve, fluorescein permeability, and TEER measurements was done by 2-way ANOVA, followed by Bonferroni’s post-hoc
test with appropriate correction for repeated measures. Comparison of
CXCL12 polarity was done via χ2 test. For all graphs, error bars represent
± 1 SEM. All statistical analysis was performed with GraphPad Prism
software, version 5.0. P values of less than 0.05 were considered significant for all comparisons.
Study approval. This study was carried out in strict accordance with the
requirements pertaining to animal subjects within the Public Health
Service Policy and USDA Animal Welfare Regulations. All experiments
were performed in compliance with Washington University Institutional
Animal Care and Use Committee (Animal Welfare Assurance A3381-01),
which approved our animal protocol (20120160, 8/3/12). All efforts were
made to minimize the suffering of animals used in this study. Postmortem
human tissues banked for research purposes are exempt from institutional
review board approval, and researchers do not have direct access to any
identifying information.
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